Publications by authors named "Xiongbin Xu"
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Bioorg Med Chem Lett
July 2024
Article Synopsis
- Abemaciclib, one of the CDK4/6 inhibitors for metastatic breast cancer, has fewer side effects due to its preference for inhibiting CDK4 over CDK6.
- Researchers discovered TQB3616 as a new preferential CDK4 inhibitor, showing better potency against cancer cells compared to approved drugs like palbociclib and abemaciclib.
- TQB3616, which has a good safety profile, entered clinical development in 2019 and is currently undergoing phase III trials.
3-Allyl-1-(2-cyano-benz-yl)-2-methyl-benzimidazol-3-ium bromide.
Acta Crystallogr Sect E Struct Rep Online
December 2007
In the title compound, C(19)H(18)N(3) (+)·Br(-), both the allyl and cyano-phenyl groups are approximately perpendicular to the central benzimidazole unit, making dihedral angles of 89.7 (2) and 85.09 (13)°, respectively.
View Article and Find Full Text PDF3-Allyl-1-(3-cyano-phenyl-methyl-ene)-2-methyl-1H-benzoimidazol-3-ium bromide monohydrate.
Acta Crystallogr Sect E Struct Rep Online
December 2007
In the title compound, C(19)H(18)N(3) (+)·Br(-)·H(2)O, the dihedral angle between the allyl group and the imidazole ring is 89.59 (14)°, while the dihedral angle between the cyanophenyl ring and the imidazole ring is 78.72 (7)°.
View Article and Find Full Text PDF